Endometrioid and Clear Cell Carcinoma of the Ovary

Brescia RJ, R J Brescia, Robert J. Brescia, N Dubin, Neil Dubin, Dubin N, R I Demopoulos, Rita I. Demopoulos, Demopoulos RI
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 1989 · vol. 8(2) , pp. 132–138 · doi:10.1097/00004347-198906000-00006 · PMID:2714931 · W2071690771
article OA: closed CC0 ⤵ 15 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study found that higher stages and higher grades of endometrioid components correlated with decreased survival in ovarian endometrioid, mixed, and clear cell carcinomas, though mixed histology and clear cell histology did not significantly alter prognosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-20 · read from full text ⓘ

This retrospective study analyzed survival outcomes for eighty-five patients diagnosed with endometrioid, clear cell, or mixed ovarian carcinomas to evaluate the impact of histological features and clinical factors. The researchers found that higher disease stages and higher grades within the endometrioid components were significantly associated with decreased five-year survival rates, whereas patient age, squamous differentiation, and the presence of coexisting endometrial carcinoma did not significantly affect prognosis. Notably, patients with clear cell carcinoma exhibited a significantly higher incidence of pelvic endometriosis compared to those with endometrioid or mixed tumors, although the presence of endometriosis itself was not linked to survival differences in this cohort. Relevance to endometriosis: This paper is centrally about endometriosis as a potential precursor or comorbidity in ovarian cancer subtypes, specifically highlighting the strong association between clear cell carcinoma and pre-existing endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Eighty-five patients, 52 with endometrioid carcinoma (EC), nine with mixed endometrioid and clear cell carcinoma (MC), and 24 with clear cell carcinoma (CC), were studied to determine if prognosis was affected by (a) mixed tumor histology, (b) grade of the endometrioid component in ECs, and MCs, (c) presence of benign or malignant squamous differentiation in ECs, (d) solid versus tubular histology in CCs, (e) endometriosis in the same ovary as the tumor or elsewhere in the pelvis, (f) tumor stage, (g) patient age, or (h) presence of a coexisting carcinoma of the endometrium. The 5 year survivals for the ECs, MCs, and CCs were 52%, 22%, and 69%, respectively, for all stages. The 5 year survivals for Stage I ECs and CCs were 82% and 93%, respectively. None of these differences were statistically significant. Higher stages of disease for all three tumor types and higher grades of the endometrioid component of the ECs and the MCs were associated with significantly decreased survival. Patients with CCs had a significantly increased incidence of pelvic endometriosis (67%) versus patients with ECs (17%) or MCs (22%) (p less than 0.001). Survival was not significantly affected by benign or malignant squamous differentiation in ECs, tubular differentiation in CCs, patient age, the presence of endometriosis, or a coexisting carcinoma of the endometrium.
Full text 1,497 characters · extracted from oa-doi-fallback · click to expand
Endometrioid and Clear Cell Carcinoma of the Ovary Factors Affecting Survival - Robert J. Brescia - Neil Dubin - Rita I. Demopoulos Summary: Eighty-five patients, 52 with endometrioid carcinoma (EC), nine with mixed endometrioid and clear cell carcinoma (MC), and 24 with clear cell carcinoma (CC), were studied to determine if prognosis was affected by (a) mixed tumor histology, (b) grade of the endometrioid component in ECs, and MCs, (c) presence of benign or malignant squamous differentiation in ECs, (d) solid versus tubular histology in CCs, (e) endometriosis in the same ovary as the tumor or elsewhere in the pelvis, (f) tumor stage, (g) patient age, or (h) presence of a coexisting carcinoma of the endometrium. The 5 year survivals for the ECs, MCs, and CCs were 52%, 22%, and 69%, respectively, for all stages. The 5 year survivals for Stage I ECs and CCs were 82% and 93%, respectively. None of these differences were statistically significant. Higher stages of disease for all three tumor types and higher grades of the endometrioid component of the ECs and the MCs were associated with significantly decreased survival. Patients with CCs had a significantly increased incidence of pelvic endometriosis (67%) versus patients with ECs (17%) or MCs (22%) (p < 0.001). Survival was not significantly affected by benign or malignant squamous differentiation in ECs, tubular differentiation in CCs, patient age, the presence of endometriosis, or a coexisting carcinoma of the endometrium

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Endometriosis Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adult Aged Aged, 80 and over Endometriosis Endometriosis Female Humans Middle Aged Neoplasm Staging Ovarian Neoplasms Ovarian Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (15)

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0 · commercial use OK